Clioquinol: To harm or heal.

ATP-Binding Cassette Transporters / genetics Animals Anti-Infective Agents / adverse effects Asian People / genetics Clioquinol / adverse effects Cyclic AMP / metabolism Cyclic AMP-Dependent Protein Kinases / metabolism Humans Myelitis / chemically induced Neoplasms / drug therapy Neurodegenerative Diseases / drug therapy Optic Neuritis / chemically induced Polymorphism, Single Nucleotide Syndrome
ABC transporters Alzheimer's disease Cancer Clioquinol Neurodegenerative diseases Pharmacogenomics SNPs

Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
07 2019
Historique:
received: 17 12 2018
accepted: 14 03 2019
pubmed: 23 3 2019
medline: 28 4 2020
entrez: 23 3 2019
Statut: ppublish

Résumé

Clioquinol, one of the first mass-produced drugs, was considered safe and efficacious for many years. It was used as an antifungal and an antiprotozoal drug until it was linked to an outbreak of subacute myelo-optic neuropathy (SMON), a debilitating disease almost exclusively confined to Japan. Today, new information regarding clioquinol targets and its mechanism of action, as well as genetic variation (SNPs) in efflux transporters in the Japanese population, provide a unique interpretation of the existing phenomena. Further understanding of clioquinol's role in the inhibition of cAMP efflux and promoting apoptosis might offer promise for the treatment of cancer and/or neurodegenerative diseases. Here, we highlight recent developments in the field and discuss possible connections, hypotheses and perspectives in clioquinol-related research.

Identifiants

DOI: 10.1016/j.pharmthera.2019.03.009 PMID: 30898518 PMC: PMC6571072
pubmed: 30898518
pii: S0163-7258(19)30048-8
doi: 10.1016/j.pharmthera.2019.03.009
pmc: PMC6571072
mid: NIHMS1524256
pii:
doi:

Substances chimiques

ATP-Binding Cassette Transporters 0
Anti-Infective Agents 0
Clioquinol 7BHQ856EJ5
Cyclic AMP E0399OZS9N
Cyclic AMP-Dependent Protein Kinases EC 2.7.11.11

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

155-163

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM121176
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA118100
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007736
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001449
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Neurotherapeutics. 2015 Jan;12(1):109-20
pubmed: 25354461
Neurobiol Aging. 2009 Oct;30(10):1608-13
pubmed: 18272254
Hum Mutat. 2008 May;29(5):659-69
pubmed: 18300232
Chemistry. 2011 Feb 25;17(9):2752-62
pubmed: 21274957
Breast Cancer Res Treat. 2011 Feb;126(1):235-9
pubmed: 21165769
ACS Chem Neurosci. 2016 Mar 16;7(3):360-6
pubmed: 26712118
Neurobiol Dis. 2011 Jun;42(3):242-51
pubmed: 21220021
Free Radic Biol Med. 2013 Sep;62:76-89
pubmed: 23142767
Methods Mol Biol. 2016;1439:227-44
pubmed: 27316999
Front Pharmacol. 2015 Jul 02;6:134
pubmed: 26191006
J Biol Chem. 2011 Mar 4;286(9):6979-88
pubmed: 21205825
J Neurochem. 2007 Dec;103(6):2462-70
pubmed: 17908236
Molecules. 2012 Mar 19;17(3):3524-38
pubmed: 22430119
Front Immunol. 2012 Aug 02;3:242
pubmed: 22876249
Brain Res. 2011 Oct 12;1417:127-36
pubmed: 21907331
Science. 2000 Nov 17;290(5495):1273-4
pubmed: 11185394
Lancet Neurol. 2008 Sep;7(9):779-86
pubmed: 18672400
Acta Neuropathol Commun. 2016 Nov 14;4(1):119
pubmed: 27842602
Metallomics. 2016 Jun 1;8(6):628-32
pubmed: 26962965
Brain Res. 2010 Oct 28;1358:228-38
pubmed: 20727860
Mech Ageing Dev. 1979 Feb;9(3-4):291-301
pubmed: 374897
Lancet Neurol. 2015 Jan;14(1):39-47
pubmed: 25467848
Methods Mol Biol. 2008;445:77-88
pubmed: 18425443
Cancer Res. 2008 Jul 1;68(13):4983-9
pubmed: 18593894
Cancer Sci. 2010 Nov;101(11):2404-10
pubmed: 20718756
Curr Pharm Biotechnol. 2011 Apr;12(4):656-73
pubmed: 21118088
Exp Neurol. 2007 Nov;208(1):145-58
pubmed: 17916353
Breast Cancer Res Treat. 2013 Apr;138(2):652-3
pubmed: 23646373
ACS Med Chem Lett. 2015 Aug 10;6(9):1025-9
pubmed: 26396692
Anticancer Res. 2010 Dec;30(12):5189-94
pubmed: 21187511
Nat Genet. 2006 Mar;38(3):324-30
pubmed: 16444273
J Gastroenterol. 2010 Oct;45(10):1014-21
pubmed: 20393862
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13217-21
pubmed: 12244210
J Alzheimers Dis. 2010;19(1):311-23
pubmed: 20061647
Front Biosci (Landmark Ed). 2012 Jan 01;17:451-72
pubmed: 22201755
Neuron. 2013 Mar 6;77(5):929-41
pubmed: 23473322
Neuron. 2001 Jun;30(3):665-76
pubmed: 11430801
Biomed Res Int. 2016;2016:7670483
pubmed: 27057547
Aging Cell. 2008 Jan;7(1):47-57
pubmed: 18005252
Brain Res Brain Res Rev. 2003 Jan;41(1):44-56
pubmed: 12505647
J Alzheimers Dis. 2014;38(3):611-20
pubmed: 24037034
J Biol Chem. 2011 Apr 22;286(16):14639-48
pubmed: 21367856
Exp Neurol. 2013 Sep;247:80-90
pubmed: 23570902
BMC Immunol. 2014 Oct 31;15:52
pubmed: 25367365
Clin Pharmacol Ther. 2016 Nov;100(5):441-453
pubmed: 27447939
Mol Neurobiol. 2018 Mar;55(3):2471-2482
pubmed: 28386847
Jpn J Med Sci Biol. 1971 Aug;24(4):195-216
pubmed: 4944758
Anticancer Agents Med Chem. 2010 Oct 1;10(8):617-24
pubmed: 21182469
Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2517-27
pubmed: 23507145
ACS Chem Neurosci. 2016 Jan 20;7(1):119-29
pubmed: 26481462
Nat Rev Cancer. 2017 Sep;17(9):528-542
pubmed: 28751651
BMC Genet. 2009 Aug 04;10:42
pubmed: 19650936
BMC Immunol. 2008 Jun 05;9:26
pubmed: 18534032
Neuroscience. 2013 Oct 22;251:51-65
pubmed: 22687952
Neurobiol Aging. 2015 Dec;36(12):3228-3238
pubmed: 26453000
FASEB J. 2009 Jun;23(6):2001-13
pubmed: 19383836
Cell. 2002 Mar 8;108(5):689-703
pubmed: 11893339
Nat Med. 2009 Apr;15(4):356-9
pubmed: 19350001
J Neurosci. 2012 Aug 15;32(33):11390-5
pubmed: 22895721
Clin Cancer Res. 2009 Mar 1;15(5):1762-9
pubmed: 19240178
Science. 1971 Jul 23;173(3994):347-9
pubmed: 5559907
Neurobiol Aging. 2008 Oct;29(10):1485-93
pubmed: 17442458
Pharmacogenomics J. 2015 Aug;15(4):380-4
pubmed: 25403995
Oncotarget. 2016 Jun 7;7(23):33960-82
pubmed: 27129155
Breast Cancer Res Treat. 2013 Feb;137(3):773-82
pubmed: 23288347
Pharm Biol. 2016;54(1):18-24
pubmed: 25857808
J Hum Genet. 2009 Sep;54(9):499-503
pubmed: 19644513
Br J Prev Soc Med. 1975 Sep;29(3):157-69
pubmed: 127638
Biochem Pharmacol. 2012 Mar 15;83(6):705-14
pubmed: 22119240
Mol Biol Cell. 2015 Jan 1;26(1):43-54
pubmed: 25378583
Breast Cancer Res Treat. 2011 Oct;129(3):993-9
pubmed: 21655989
Brain Res. 2001 Dec 13;922(1):148-52
pubmed: 11730714
Neurosci Lett. 2009 Mar 13;452(2):90-5
pubmed: 19154776
Neurosci Res. 2011 May;70(1):24-9
pubmed: 21352859
Nat Rev Cancer. 2010 Feb;10(2):147-56
pubmed: 20075923
Brain Res. 1999 Nov 6;846(2):265-7
pubmed: 10556645
Acta Pharm. 2015 Dec;65(4):463-71
pubmed: 26677902
Pharm Res. 2018 Mar 5;35(4):83
pubmed: 29508078
Oncotarget. 2016 Jul 19;7(29):45597-45607
pubmed: 27323809
Curr Drug Metab. 2007 May;8(4):365-78
pubmed: 17504224
J Pharmacol Exp Ther. 2008 Jun;325(3):859-68
pubmed: 18364470

Auteurs

Dominique R Perez (DR)

University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Larry A Sklar (LA)

University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Alexandre Chigaev (A)

University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. Electronic address: achigaev@salud.unm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Transporteurs ABC › Clioquinol: To harm or heal.
questionsmedicales.fr › Eucaryotes › Animaux › Clioquinol: To harm or heal.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Clioquinol: To harm or heal.
questionsmedicales.fr › Personnes › Asiatiques › Clioquinol: To harm or heal.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Hydroxyquinoléines › Hydroxy-8 quinoléine › Clioquinol › Clioquinol: To harm or heal.
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › AMP cyclique › Clioquinol: To harm or heal.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Cyclic Nucleotide-Regulated Protein Kinases › Cyclic AMP-Dependent Protein Kinases › Clioquinol: To harm or heal.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clioquinol: To harm or heal.
questionsmedicales.fr › Maladies du système nerveux › Myélite › Clioquinol: To harm or heal.
questionsmedicales.fr › Tumeurs › Clioquinol: To harm or heal.
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Clioquinol: To harm or heal.
questionsmedicales.fr › Maladies de l'oeil › Atteintes du nerf optique › Névrite optique › Clioquinol: To harm or heal.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › Clioquinol: To harm or heal.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Maladie › Syndrome › Clioquinol: To harm or heal.